Literature DB >> 16276171

Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy.

Michael Darmon1, Guillaume Thiery, Magali Ciroldi, Sandra de Miranda, Lionel Galicier, Emmanuel Raffoux, Jean-Roger Le Gall, Benoît Schlemmer, Elie Azoulay.   

Abstract

OBJECTIVE: Patients with newly diagnosed cancer responsible for organ failures may require intensive care unit (ICU) admission and immediate chemotherapy. Outcomes in this population have not been studied.
DESIGN: Prospective observational cohort study.
SETTING: Teaching hospital.
SUBJECTS: All patients admitted to the ICU, from January 1997 to June 2003, for organ failures due to newly diagnosed, untreated cancer and deemed necessary to receive immediate cancer chemotherapy.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: For the period of 6.5 yrs, 100 patients met the study criteria: 43 had acute leukemia, 37 lymphoma, and 12 solid tumors. Median Simplified Acute Physiology Score II was 39 (30-48) points, and median Logistic Organ Dysfunction score was 5 (3-7) points. Three variables were independently associated with 30-day mortality: need for vasopressor therapy (odds ratio, 6.01; 95% confidence interval, 1.86-19.4), mechanical ventilation (odds ratio, 6.36; 95% confidence interval, 1.76-22.94); and hepatic failure (odds ratio, 7.76; 95% confidence interval, 1.25-48.27). Overall survival was 60% after 30 days and 49% after 180 days.
CONCLUSIONS: Mortality was chiefly dependent on the nature and number of organ failures, not on the nature or stage of the malignancy. The 30-day and 180-day survival rates indicate that, in this selected group of patients, advanced disease at cancer diagnosis should not lead to refusal of ICU admission. Moreover, administration of chemotherapy in the intensive care unit is feasible, and although the mortality rate is high, routine ICU admission of patients with newly diagnosed cancer, specific organ failure, and the need for administration of chemotherapy in the ICU deserves evaluation.

Entities:  

Mesh:

Year:  2005        PMID: 16276171     DOI: 10.1097/01.ccm.0000181728.13354.0a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  47 in total

1.  The intensive care support of patients with malignancy: do everything that can be done.

Authors:  Elie Azoulay; Bekele Afessa
Journal:  Intensive Care Med       Date:  2005-11-25       Impact factor: 17.440

2.  Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units.

Authors:  Jae-Uk Song; Gee Young Suh; Hye Yun Park; So Yeon Lim; Seo Goo Han; Yeh Rim Kang; O Jung Kwon; Sookyoung Woo; Kyeongman Jeon
Journal:  Intensive Care Med       Date:  2012-05-17       Impact factor: 17.440

3.  Critical care management of lung cancer patients to prolong life without prolonging dying.

Authors:  Márcio Soares; Elie Azoulay
Journal:  Intensive Care Med       Date:  2009-09-19       Impact factor: 17.440

4.  Intravascular lymphoma presenting as a specific pulmonary embolism and acute respiratory failure: a case report.

Authors:  Sophie Georgin-Lavialle; Michael Darmon; Lionel Galicier; Marinos Fysekidis; Elie Azoulay
Journal:  J Med Case Rep       Date:  2009-05-12

Review 5.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

6.  Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit.

Authors:  Stephen M Pastores; Debra A Goldman; David J Shaz; Natalie Kostelecky; Ryan J Daley; Tim J Peterson; Kay See Tan; Neil A Halpern
Journal:  Cancer       Date:  2018-05-04       Impact factor: 6.860

7.  Central neurological complications in critically ill patients with malignancies.

Authors:  Stéphane Legriel; Hélène Marijon; Michael Darmon; Virginie Lemiale; Jean-Pierre Bedos; Benoît Schlemmer; Elie Azoulay
Journal:  Intensive Care Med       Date:  2009-11-12       Impact factor: 17.440

8.  Continued survival gains in recent years among critically ill myeloma patients.

Authors:  Vincent Peigne; Katerina Rusinová; Lionel Karlin; Michael Darmon; Jean-Paul Fermand; Benoît Schlemmer; Elie Azoulay
Journal:  Intensive Care Med       Date:  2008-10-14       Impact factor: 17.440

9.  Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study.

Authors:  S G Oeyen; D D Benoit; L Annemans; P O Depuydt; S J Van Belle; R I Troisi; L A Noens; P Pattyn; J M Decruyenaere
Journal:  Intensive Care Med       Date:  2012-12-18       Impact factor: 17.440

10.  Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

Authors:  Isaline Coquet; Juliette Pavie; Pierre Palmer; François Barbier; Stéphane Legriel; Julien Mayaux; Jean Michel Molina; Benoît Schlemmer; Elie Azoulay
Journal:  Crit Care       Date:  2010-06-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.